AbbVie Inc.
ABBV
Classifica tra le azioni
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Prezzo delle azioni
$288.62
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$510.03B
Variazione (1 giorno)
2.00%
Variazione (1 anno)
25.29%
Paese
US
Scambia AbbVie Inc. (ABBV)
Categoria
Healthcare
Storico del prezzo dell'azione per AbbVie Inc. (ABBV)
Prezzo di chiusura più alto: $291.87 il 2026-10-01
Prezzo di chiusura più basso: $58.07 il 2014-09-01
Prezzo di chiusura più basso: $58.07 il 2014-09-01
Storico del prezzo dell'azione di AbbVie Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 5.13% |
| 2025 | 28.37% |
| 2024 | 16.37% |
| 2023 | -7.18% |
| 2022 | 27.93% |
| 2021 | 21.25% |
| 2020 | 19.12% |
| 2019 | -4.11% |
| 2018 | -5.14% |
| 2017 | 57.46% |
| 2016 | 8.22% |
| 2015 | -15.91% |
| 2014 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $1.29K | 60.87% |
US
|
|
| $259.60 | 35.29% |
US
|
|
| $148.36 | 69.32% |
US
|
|
| $512.42 | 39.12% |
CH
|
|
| $163.95 | 24.90% |
CH
|
